Logo

Tripos Stock Surges 21 Percent on Extended Pfizer Deal

Nov 15, 2004

NEW YORK, Nov. 15 (GenomeWeb News) - Shares in Tripos were up 21 percent at $5.46 in mid-afternoon trading as investors cheered news of an extended multimillion-dollar software license agreement with Pfizer.

The companies initially announced a wide area network partnership in January 2001 that Pfizer employ a "broad array" of Tripos' drug-discovery software tools, including the SYBYL and UNITY programs.

Details of the extended agreement were not disclosed.

Breaking News
The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.